Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>AU1235
AU1235 Catalog No.GC32095

Size Price Stock Qty
In stock
In stock
In stock
In stock
In stock
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 1338780-86-1 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES O=C(NC(C=CC(F)=C1F)=C1F)NC2(C[C@H](C3)C4)C[C@H]4C[C@H]3C2
Formula C17H19F3N2O M.Wt 324.34
Solubility DMSO : 6 mg/mL (18.50 mM; Need ultrasonic) Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



AU1235 is an adamantyl urea inhibitor of Mycobacterium tuberculosis.

AU1235 has a minimum inhibitory concentration (MIC) of 0.1 μg/mL (0.3 μM) (minimum bactericidal concentration of 0.1 μg/mL. AU1235 is similarly active against MDR clinical isolates of M. tb displaying resistance to isoniazid, rifampicin, and pyrazinamide in addition to streptomycin, fluoroquinolones and/or ethambutol. AU1235 also inhibits Mycobacterium smegmatis and Mycobacterium fortuitum (MICs=3.2 to 6.4 μg/mL). AU1235 (10 times MIC) does not increase the killing effect within the first 7 days indicating that the killing is time-dependent rather than concentration-dependent. In an anaerobic model involving non-replicating M. tb H37Rv bacilli, AU1235 at 10 μg/mL shows no detectable activity suggesting that it acts on a biosynthetic pathway required for active bacterial multiplication. AU1235 does not inhibit the biosynthesis of mycolic acids per se but specifically their ability to be transferred onto their cell wall and outer membrane acceptors, possibly as a result of altered TMM translocation across the plasma membrane[1].

[1]. Grzegorzewicz AE, et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol. 2012 Feb 19;8(4):334-41.